Health Care • Biotechnology: Pharmaceutical Preparations
$3.31 ▲ +0.07
(+2.16%)
MKT CAP: $356.7M • VOL: 18.78M
52W L $0 52W H $4
ROARABLE / RQD
D- • 40/100
PIOTROSKI
3 / 9
CYPH // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$41.1M | -$70.1M | -$87.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | $5.0M | -$68.0M | -$81.0M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$43.9M | -$60.3M | -$43.8M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$43.9M | -$60.3M | -$43.8M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -23.3% | -45.0% | — |
| Cash & Short-Term Equivalents | $14.0M | $47.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $153.5M | $35.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CYPH.